OncoMatch/Non-Hodgkin Lymphoma (NHL)/MYC rearrangement
Non-Hodgkin Lymphoma (NHL)MYC rearrangement Clinical Trials
MYC rearrangements define Burkitt lymphoma (near-universally) and high-grade B-cell lymphoma (double/triple-hit with BCL2/BCL6) among NHL subtypes, and confer aggressive biology and poor outcomes with standard regimens. Intensive regimens (R-CODOX-M/IVAC, DA-EPOCH-R) are used in MYC-rearranged aggressive NHL. Trials investigate first-line CAR-T therapy, polatuzumab vedotin combinations, and novel MYC-directed approaches for this unmet-need population.
Top recruiting MYC rearrangement Non-Hodgkin Lymphoma (NHL) trials
Ranked by phase and US site count. See all 18 trials matched to your profile →
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Nordic Lymphoma Group
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
Browse other molecular targets with active Non-Hodgkin Lymphoma (NHL) trials.